Factors associated with accepting treat to target approach
| Treat to target not accepting | Treat to target accepting | Univariate analysis | Binary logistic regression | |
| Diagnosis (n) | ||||
| CD | 54 | 90 | B=−1.28 | |
| UC | 38 | 98 | ||
| IBD-U | 8 | 10 | p=0.2 | p=0.021 |
| IBD-related surgery (n) | B=0.95 | |||
| Yes | 18 | 52 | ||
| No | 82 | 146 | p=0.2 | p=0.08 |
| Mesalazine treatment (n) | ||||
| Never | 26 | 45 | B=−0.49 | |
| Previous | 34 | 61 | ||
| Current | 40 | 92 | p=0.7 | p=0.3 |
| Thiopurine treatment (n) | ||||
| Never | 38 | 72 | B=0.3 | |
| Previous | 33 | 64 | ||
| Current | 29 | 62 | p=0.9 | p=0.5 |
| First-line anti-TNF treatment (n) | ||||
| Never | 67 | 126 | B=−0.56 | |
| Previous | 20 | 25 | ||
| Current | 13 | 47 | p=0.08 | p=0.3 |
| Second-line anti-TNF treatment (n) | ||||
| Never | 84 | 186 | B=0.63 | |
| Previous | 1 | 6 | ||
| Current | 12 | 6 | p=0.012 | p=0.4 |
| Disease duration (median in years, not normally distributed) | 7 | 8 | p=0.4 | B=−0.004 p=0.9 |
| Age (mean in years, normally distributed) | 44.7 | 48.7 | p=0.07 | B=−0.006 p=0.7 |
| Patient knowledge (mean, normally distributed) | 4 | 4 | p=0.09 | B=0.66 p=0.5 |
| CRP (available for 281 patients, median, not normally distributed) | 1 | 1 | p=0.7 | B=0.59 p=0.1 |
| FC (186 samples returned, median, not normally distributed) | 104 | 111 | p=0.7 | B=0 p=0.4 |
| Patient-reported current disease control (10-point Likert scale, median, not normally distributed) | 9 | 8 | p=0.6 | B=0.13 p=0.6 |
| Patient-reported 3-year disease control (10-point Likert scale, median, not normally distributed) | 7 | 7 | p=0.6 | B=0.04 p=0.6 |
| HADS anxiety (median, not normally distributed) | 8 | 7 | p=0.2 | B=−0.26 p=0.8 |
| HADS depression (median, not normally distributed) | 7 | 6 | p=0.4 | B=−0.13 p=0.2 |
| Medication adherence (MARS, median, not normally distributed) | 19 | 20 | p=0.032 | B=0.16 p=0.039 |
| Quality of life (SIBDQ, median, not normally distributed) | 54 | 56 | p=0.4 | B=−0.55 p=0.1 |
CD, Crohn’s disease; FC, faecal calprotectin; HADS, Hospital Anxiety and Depression Scale; IBD, inflammatory bowel disease; MARS, Medication Adherence Report Scale; NB, where figures do not add up to 298 the relevant status was not known for some patients; SIBDQ, Short IBD Quality of Life Questionnaire; TNF, tumour necrosis factor; UC, ulcerative colitis.